Cyteir Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q2 2020 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cyteir Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2020 to Q3 2023.
  • Cyteir Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2023 was $599K, a 49.8% decline year-over-year.
  • Cyteir Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2023 was $3.29M, a 33.6% decline year-over-year.
  • Cyteir Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $4.68M, a 35.1% increase from 2021.
  • Cyteir Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $3.47M, a 642% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 $3.29M $599K -$594K -49.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-06
Q2 2023 $3.88M $776K -$589K -43.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $4.47M $1.04M -$213K -17% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-10
Q4 2022 $4.68M $869K -$264K -23.3% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-23
Q3 2022 $4.95M $1.19M +$121K +11.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $4.83M $1.37M +$593K +76.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $4.23M $1.26M +$767K +157% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $3.47M $1.13M Oct 1, 2021 Dec 31, 2021 10-K 2023-03-23
Q3 2021 $1.07M +$937K +694% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $772K +$665K +621% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 $488K Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q3 2020 $135K Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $107K Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.